Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04852302|
Recruitment Status : Enrolling by invitation
First Posted : April 21, 2021
Last Update Posted : October 21, 2022
Psychological distress affects many people diagnosed with a primarym central nervous system tumor (CNST). Distress can include negative feelings such as anger, fear, or sadness. Researchers want to see if a type of therapy called CALM can help. It promotes well-being in people who have cancer that cannot be cured.
To find out if the CALM therapy can help people with a CNST suffering from distress.
English-speaking adults ages 18 and older who have a CNST and are taking part in NIH protocol #16C0151.
This study will not take place in person. It will be done by smartphone, computer, or tablet.
Participants will fill out 7 surveys. The surveys will take 40 to 60 minutes to complete. They are all electronic. They will ask about physical and emotional symptoms, depression, feelings about death and dying, feelings about close relationships, and general well-being.
Participants will be assigned to a CALM therapist. They will have 3 to 6 individual therapy sessions in 6 months. Each session will last 45 to 60 minutes. Sessions may be audio recorded. If needed, participants may have extra sessions.
CALM includes symptom management and discussions of meaning, purpose, and mortality.
Participants may have a family member take part in at least one CALM session with them.
After the third CALM session, participants will be asked questions about CALM.
After 3 and 6 months, participants will complete the 7 surveys again.
Participation will last about 6 months.
|Condition or disease||Intervention/treatment||Phase|
|Depression||Behavioral: CALM Therapy||Not Applicable|
- Psychological distress is an emotional state experienced by primary central nervous system tumor (PCNST) patients throughout the illness trajectory. It can often be under identified in this patient population.
- Limited therapeutic interventions in managing distress symptoms can allow symptoms to linger without tailored mechanisms to manage the emotional challenges experienced with a tumor diagnosis. Individualized therapy in advanced cancer patients is a preferred method over pharmacological interventions when managing psychological distress, but more evidence-based research is needed to address the benefits.
- The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients. Previous studies implementing the CALM intervention have focused on metastatic and advanced cancer patients and have reported positive effects. Implementing the CALM intervention in a sample of PCNST patients will be one of the first studies to identify the preliminary effectiveness.
-To demonstrate the effects of the CALM intervention in reduction of depressive symptoms using the PROMIS-Depression scale in PCNST participants, from baseline to 6 months.
- Adult participants greater than or equal to 18 years of age with a PCNST diagnosis who are undergoing standard of care or experimental treatment.
- The ability of the subject to speak English
- Subjects who have a life expectancy of at least 3 months from time of study entry to allow for participation in the 3 required sessions.
- The ability of the subject to understand and willing to sign a written informed consent document as determined by the assessment of the clinical team.
- A total of 100 participants will be enrolled
- Neuro-Oncology participants being seen in the clinical center or receiving telehealth services will be screened to participate. Participants will be assigned a CALM therapist and all sessions will be completed remotely.
Data from standardized measures will be collected at 3 timepoints (Baseline, 3 months, 6 months) and qualitative interviews will be completed after the 3rd CALM session for a select number of participants until data saturation is reached (estimated to be 15-30).
-Approximate time for sessions is 45-60 minutes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Central Nervous System Tumor|
|Actual Study Start Date :||August 11, 2021|
|Estimated Primary Completion Date :||November 1, 2023|
|Estimated Study Completion Date :||November 1, 2023|
Experimental: Arm 1
Remote CALM therapy for participants with newly or recurrent PCNST
Behavioral: CALM Therapy
The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
- reduction of depressive symptoms using the PROMIS-Depression scale in PCNST participants [ Time Frame: baseline to 6 months ]To demonstrate the effects of the CALM intervention in reduction of depressive symptoms using the PROMIS-Depression scale in PCNST participants, from baseline to 6 months.
- reduction of depressive symptoms using the PROMIS-Depression scale in PCNST participants [ Time Frame: baseline compared at 3 month ]To demonstrate the short-term effects of the CALM intervention in reduction of depressive symptoms using the PROMIS-Depression scale in PCNST participants from baseline to 3 months.
- reduction of anxiety score using the Death and Dying Distress Scale (DADDS) [ Time Frame: 3 and 6 months compared to baseline ]To determine the effects of the CALM intervention on death anxiety at both 3 and 6 months, compared to baseline.
- feasibility of implementing CALM remotely [ Time Frame: baseline to 6 months ]To describe the feasibility of implementing CALM remotely in a PCNST population, including eligibility, accrual, compliance, adverse effects, study completion, and participant satisfaction with the intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04852302
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Terri S Armstrong, C.R.N.P.||National Cancer Institute (NCI)|